Suchergebnisse - "Falk, Ingrid"

PubPharm (35)

1

ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients

enthalten in: Basic & clinical pharmacology & toxicology | 2018

von Björn, N. | Jakobsen Falk, I. | Vergote, I. | +1

2

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma : results from a phase IV observational study and subsequent phase II clinical trial

enthalten in: Cancer chemotherapy and pharmacology | 2018

von Jakobsen Falk, I. | Lund, J. | Gréen, H. | +12

3

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Jakobsen Falk, I. | Lund, J. | Gréen, H. | +12

4

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Jakobsen Falk, I. | Lund, J. | Gréen, H. | +12

5

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Jakobsen Falk, I. | Lund, J. | Gréen, H. | +12

6

Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis

enthalten in: Oncotarget | 2015

von Mosrati, M. | Willander, K. | Falk, I. | +6

7

TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome

enthalten in: European journal of haematology | 2015

von Falk, I. | Willander, K. | Chaireti, R. | +6

8

TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome

enthalten in: European journal of haematology | 2015

von Falk, I. | Willander, K. | Chaireti, R. | +6

9

Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype

enthalten in: British journal of haematology | 2014

von Jakobsen Falk, I. | Fyrberg, A. | Paul, E. | +9

10

Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia

enthalten in: Biomarker Research | 2014

von Willander, K. | Falk, I. | Chaireti, R. | +5